CYP2A6 (cytochrome P450, family 2, subfamily A, polypeptide 6)

2009-12-01   Naoki Inui 

Department of Respiratory Medicine, Hamamatsu University School of Medicine, Shizuoka, Japan

Identity

HGNC
LOCATION
19q13.2
LOCUSID
ALIAS
CPA6,CYP2A,CYP2A3,CYPIIA6,P450C2A,P450PB
FUSION GENES

DNA/RNA

Description

9 exons. The gene sequence: 6910 bp.

Transcription

1751 base pairs.

Proteins

Note

CYP2A6 is an enzyme responsible for the metabolism of clinically used pharmaceuticals such as coumarin and valproic acid, several carcinogens such as 4-(methylnitrosamine)-1-(3-pyridyl)-1-butanone and aflatoxin B1, nicotine and for the bioactivation process of tegafur to 5-FU.
The formation of 5-FU from tegafur was inhibited over 90% by a CYP2A6 selective antibody using human liver microsomes. CYP2A6 shows large interindividual and interethnic variations in its expression levels and conversion activities, which are mainly attributed to CYP2A6 genetic polymorphisms. The expression is induced by Phenobarbital and dexamethasone.

Description

494 amino acids.

Expression

Liver.

Localisation

Endoplasmic reticulum membrane, peripheral membrane protein, microsome membrane.

Function

Oxidation, reduction, coumarin 7-hydroxylase activity, electron carrier activity, heme binding, iron ion binding, oxygen binding, the hydroxylation of the anti-cancer drugs.
Atlas Image
Example of CYP2A6 function.
(A) Oxidation: CYP2A6 is responsible for converting nicotine into the inactive metabolite nicotine delta 1(5)-iminuim ion, cotinine.
(B) Oxidation: Camphor is oxidized to 5-exo-hydroxycamphor.
(C) Hydroxylation: CYP2A6 is an enzyme responsible for the metabolism of clinically used pharmaceuticals, tegafur. Tegafur is converted enzymatically to 5-FU to exert its antitumor activity. Tegafur is converted enzymatically to 5-FU to exert its antitumor activity.
(D) Hydroxylation: Coumarin is hydroxylated to 7-hydroxycoumarin.

Homology

Belongs to the cytochrome P450 family.

Mutations

Note

CYP2A6 shows large interindividual and interethnic variations in its expression levels and conversion activities, which are mainly attributed to CYP2A6 genetic polymorphisms. These alleles are derived from single nucleotide polymorphisms in the regulatory and coding regions, deletion mutations and conversions. Polymorphisms in the CYP2A6 gene affect enzyme activity. CYP2A6*2, a polymorphism that a single base mutation (1799T>A) cause an amino acid change from leucine at residue 160 to histidine, functionally shows no enzymatic activity in vivo and in vitro. While in Caucasian this type allele has been found in 1.1-3.0%, there is no report in Asian. CYP2A6*4C, which is a whole deleted allele for the human CYP2A6 gene, is a major mutant allele associated with decreased metabolic activity. CYP2A6*4C is relatively common in Asian populations, with estimated allele frequency of 20% in the Japanese, whereas the allele frequency is 0.5-1.0% in European. CYP2A6*7 and CYP2A6*9, a gene conversion in the 3 flanking region (6558T>C) and a point mutation in the TATA box (-48T>G), respectively, are associated with poor nicotine metabolism.
There are many alleles that have been listed by the Human CYP Allele Nomenclature Committee.

Implicated in

Entity name
Lung cancer
Note
Polymorphisms in the CYP2A6 gene that affect enzyme activity and susceptibility to lung cancer have been identified. Smoking is regarded as the main cause of lung cancer. CYP2A6 has responsible for the conversion of nicotine to inactive metabolite cotinine. A number of studies have demonstrated that CYP2A6 genetic variations are associated with nicotine kinetics and smoking behavior. People with CYP2A6 genetic variations, poor metabolizers of CYP2A6, were less likely to be smokers and tended to smoke fewer cigarettes per day.
Disease
There is the possibility that CYP2A6 associated smoking-related cancer, such as lung cancer, esophageal, gastric and colorectal cancer.
Prognosis
Poor metabolizers of CYP2A6 were less likely to be smokers and tended to smoke fewer cigarettes.

Bibliography

Pubmed IDLast YearTitleAuthors
152037952004A meta-analytic review of the CYP2A6 genotype and smoking behavior.Carter B et al
189364362009Prevalence in the United States of selected candidate gene variants: Third National Health and Nutrition Examination Survey, 1991-1994.Chang MH et al
186982292008Genetic polymorphisms of CYP2A6 affect the in-vivo pharmacokinetics of pilocarpine.Endo T et al
75814811995The CYP2A gene subfamily: species differences, regulation, catalytic activities and role in chemical carcinogenesis.Fernandez-Salguero P et al
153085892004Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers.Fujieda M et al
111062612000Bioactivation of tegafur to 5-fluorouracil is catalyzed by cytochrome P-450 2A6 in human liver microsomes in vitro.Ikeda K et al
182128002008The CYP2A6*4 allele is determinant of S-1 pharmacokinetics in Japanese patients with non-small-cell lung cancer.Kaida Y et al
124338262002Effects of olopatadine, a new antiallergic agent, on human liver microsomal cytochrome P450 activities.Kajita J et al
161767982005Genetic polymorphism of CYP2A6 as one of the potential determinants of tobacco-related cancer risk.Kamataki T et al
112972642001Involvement of microsomal cytochrome P450 and cytosolic thymidine phosphorylase in 5-fluorouracil formation from tegafur in human liver.Komatsu T et al
18894151991Isolation and characterization of a cytochrome P450 of the IIA subfamily from human liver microsomes.Maurice M et al
23343981990Identification of the human liver cytochrome P-450 responsible for coumarin 7-hydroxylase activity.Miles JS et al
169524952006Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations.Nakajima M et al
119274982002CYP2A6 activity determined by caffeine phenotyping: association with colorectal cancer risk.Nowell S et al
105442571999Identification and characterisation of novel polymorphisms in the CYP2A locus: implications for nicotine metabolism.Oscarson M et al
38562611985Isolation and sequence of a human cytochrome P-450 cDNA clone.Phillips IR et al
156712012005Transcriptional regulation of the human CYP2A6 gene.Pitarque M et al
179169052007Polymorphisms of GSTP1 and GSTT1, but not of CYP2A6, CYP2E1 or GSTM1, modify the risk for esophageal cancer in a western population.Rossini A et al
186667532006Genetic and environmental influences on therapeutic and toxicity outcomes: studies with CYP2A6.Satarug S et al
154757352004Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians.Schoedel KA et al
112593492001Variable CYP2A6-mediated nicotine metabolism alters smoking behavior and risk.Tyndale RF et al
40114501985RFLP for a human cytochrome P-450 gene at 19q13.1-qter (HGM8 provisional designation CYPI).Wainwright BJ et al
128441372003Effects of polymorphism in promoter region of human CYP2A6 gene (CYP2A6*9) on expression level of messenger ribonucleic acid and enzymatic activity in vivo and in vitro.Yoshida R et al

Other Information

Locus ID:

NCBI: 1548
MIM: 122720
HGNC: 2610
Ensembl: ENSG00000255974

Variants:

dbSNP: 1548
ClinVar: 1548
TCGA: ENSG00000255974
COSMIC: CYP2A6

RNA/Proteins

Gene IDTranscript IDUniprot
ENSG00000255974ENST00000301141P11509
ENSG00000255974ENST00000600495M0R2Z4

Expression (GTEx)

0
100
200
300
400
500
600

Pathways

PathwaySourceExternal ID
Caffeine metabolismKEGGko00232
Retinol metabolismKEGGko00830
Metabolism of xenobiotics by cytochrome P450KEGGko00980
Drug metabolism - cytochrome P450KEGGko00982
Drug metabolism - other enzymesKEGGko00983
Caffeine metabolismKEGGhsa00232
Retinol metabolismKEGGhsa00830
Metabolism of xenobiotics by cytochrome P450KEGGhsa00980
Drug metabolism - cytochrome P450KEGGhsa00982
Drug metabolism - other enzymesKEGGhsa00983
Metabolic pathwaysKEGGhsa01100
Chemical carcinogenesisKEGGhsa05204
Chemical carcinogenesisKEGGko05204
MetabolismREACTOMER-HSA-1430728
Biological oxidationsREACTOMER-HSA-211859
Phase 1 - Functionalization of compoundsREACTOMER-HSA-211945
Cytochrome P450 - arranged by substrate typeREACTOMER-HSA-211897
XenobioticsREACTOMER-HSA-211981
CYP2E1 reactionsREACTOMER-HSA-211999

Protein levels (Protein atlas)

Not detected
Low
Medium
High

PharmGKB

Entity IDNameTypeEvidenceAssociationPKPDPMIDs
PA10075esomeprazoleChemicalLabelAnnotationassociated
PA128406956fluorouracilChemicalVipGeneassociated15940289, 16378601, 18698229, 19238117, 19604090, 19921195, 20155256, 21494765, 21521021, 14981342
PA131285527oxaliplatinChemicalVariantAnnotationnot associatedPD
PA134521193coumarinChemicalClinicalAnnotation, VariantAnnotation, VipGeneassociatedPK11038160, 12325023, 15993850, 2322567, 10544257, 10923861, 11278503, 11394901, 11779172, 12325023, 12844137, 14583682, 15900015, 15993850, 16041240, 16679388, 21521021, 27339126, 9409631, 9827545
PA164712720Drugs used in nicotine dependenceChemicalClinicalAnnotationassociatedPD26132489
PA164781343vareniclineChemicalMultilinkAnnotationassociated25588294
PA165111696artemisininChemicalPathway, VipGeneassociated12920490, 18064444, 18350255, 18979093, 19851082, 19926036, 12844133
PA165111697artesunateChemicalPathway, VipGeneassociated12920490, 18064444, 18350255, 18979093, 19851082, 19926036, 12844133
PA165111698artemetherChemicalVipGeneassociated12920490, 18064444, 18350255, 18979093, 19851082, 19926036, 12844133
PA165260403arteetherChemicalVipGeneassociated12920490, 18064444, 18350255, 18979093, 19851082, 19926036, 12844133
PA165924691CYP2A6*1B1HaplotypeVipGeneassociated15940289, 16378601, 21494765, 21521021, 14981342
PA165924692CYP2A6*1B2HaplotypeVipGeneassociated15940289, 16378601, 21494765, 21521021, 14981342
PA165924693CYP2A6*1B3HaplotypeVipGeneassociated15940289, 16378601, 21494765, 21521021, 14981342
PA165924694CYP2A6*1B4HaplotypeVipGeneassociated15940289, 16378601, 21494765, 21521021, 14981342
PA165924695CYP2A6*1B5HaplotypeVipGeneassociated15940289, 16378601, 21494765, 21521021, 14981342
PA165924696CYP2A6*1B6HaplotypeVipGeneassociated15940289, 16378601, 21494765, 21521021, 14981342
PA165924697CYP2A6*1B7HaplotypeVipGeneassociated15940289, 16378601, 21494765, 21521021, 14981342
PA165924698CYP2A6*1B8HaplotypeVipGeneassociated15940289, 16378601, 21494765, 21521021, 14981342
PA165924699CYP2A6*1B9HaplotypeVipGeneassociated15940289, 16378601, 21494765, 21521021, 14981342
PA165924700CYP2A6*1B10HaplotypeVipGeneassociated15940289, 16378601, 21494765, 21521021, 14981342
PA165924701CYP2A6*1B11HaplotypeVipGeneassociated15940289, 16378601, 21494765, 21521021, 14981342
PA165924702CYP2A6*1B12HaplotypeVipGeneassociated15940289, 16378601, 21494765, 21521021, 14981342
PA165924703CYP2A6*1B13HaplotypeVipGeneassociated15940289, 16378601, 21494765, 21521021, 14981342
PA165924704CYP2A6*1B14HaplotypeVipGeneassociated15940289, 16378601, 21494765, 21521021, 14981342
PA165924705CYP2A6*1B15HaplotypeVipGeneassociated15940289, 16378601, 21494765, 21521021, 14981342
PA165924706CYP2A6*1B16HaplotypeVipGeneassociated15940289, 16378601, 21494765, 21521021, 14981342
PA165924707CYP2A6*1B17HaplotypeVipGeneassociated15940289, 16378601, 21494765, 21521021, 14981342
PA165924717CYP2A6*1X2AHaplotypeVipGeneassociated17267622, 19238117, 20155256, 10999944
PA165924718CYP2A6*1X2BHaplotypeVipGeneassociated17267622, 19238117, 20155256, 10999944
PA165924719CYP2A6*2HaplotypeVipGeneassociated10999944, 11180041, 11434509, 11684323, 15225612, 15475735, 15660270, 16272956, 16952495, 17112802, 17130279, 19225447, 19238117, 9827545, 10544257
PA165924721CYP2A6*4AHaplotypeVipGeneassociated10544257, 10999944, 11241319, 11725533, 11779172, 12042667, 12223434, 12749606, 12844137, 14981342, 15265511, 15308589, 15475735, 15660270, 15940289, 15980104, 16272956, 16402128, 16452582, 16891249, 16952495, 17130279, 17220563, 18212800, 18380793, 18698229, 19225447, 19238117, 19604090, 19845430, 19921195, 20089352, 20155256, 20596643, 21494765, 21521021, 10448083
PA165924722CYP2A6*4BHaplotypeVipGeneassociated10544257, 10999944, 11241319, 11725533, 11779172, 12042667, 12223434, 12749606, 12844137, 14981342, 15265511, 15308589, 15475735, 15660270, 15940289, 15980104, 16272956, 16402128, 16452582, 16891249, 16952495, 17130279, 17220563, 18212800, 18380793, 18698229, 19225447, 19238117, 19604090, 19845430, 19921195, 20089352, 20155256, 20596643, 21494765, 21521021, 10448083
PA165924723CYP2A6*4CHaplotypeVipGeneassociated10544257, 10999944, 11241319, 11725533, 11779172, 12042667, 12223434, 12749606, 12844137, 14981342, 15265511, 15308589, 15475735, 15660270, 15940289, 15980104, 16272956, 16402128, 16452582, 16891249, 16952495, 17130279, 17220563, 18212800, 18380793, 18698229, 19225447, 19238117, 19604090, 19845430, 19921195, 20089352, 20155256, 20596643, 21494765, 21521021, 10448083
PA165924724CYP2A6*4DHaplotypeVipGeneassociated10544257, 10999944, 11241319, 11725533, 11779172, 12042667, 12223434, 12749606, 12844137, 14981342, 15265511, 15308589, 15475735, 15660270, 15940289, 15980104, 16272956, 16402128, 16452582, 16891249, 16952495, 17130279, 17220563, 18212800, 18380793, 18698229, 19225447, 19238117, 19604090, 19845430, 19921195, 20089352, 20155256, 20596643, 21494765, 21521021, 10448083
PA165924725CYP2A6*4EHaplotypeVipGeneassociated10544257, 10999944, 11241319, 11725533, 11779172, 12042667, 12223434, 12749606, 12844137, 14981342, 15265511, 15308589, 15475735, 15660270, 15940289, 15980104, 16272956, 16402128, 16452582, 16891249, 16952495, 17130279, 17220563, 18212800, 18380793, 18698229, 19225447, 19238117, 19604090, 19845430, 19921195, 20089352, 20155256, 20596643, 21494765, 21521021, 10448083
PA165924726CYP2A6*4FHaplotypeVipGeneassociated10544257, 10999944, 11241319, 11725533, 11779172, 12042667, 12223434, 12749606, 12844137, 14981342, 15265511, 15308589, 15475735, 15660270, 15940289, 15980104, 16272956, 16402128, 16452582, 16891249, 16952495, 17130279, 17220563, 18212800, 18380793, 18698229, 19225447, 19238117, 19604090, 19845430, 19921195, 20089352, 20155256, 20596643, 21494765, 21521021, 10448083
PA165924727CYP2A6*4GHaplotypeVipGeneassociated10544257, 10999944, 11241319, 11725533, 11779172, 12042667, 12223434, 12749606, 12844137, 14981342, 15265511, 15308589, 15475735, 15660270, 15940289, 15980104, 16272956, 16402128, 16452582, 16891249, 16952495, 17130279, 17220563, 18212800, 18380793, 18698229, 19225447, 19238117, 19604090, 19845430, 19921195, 20089352, 20155256, 20596643, 21494765, 21521021, 10448083
PA165924728CYP2A6*4HHaplotypeVipGeneassociated10544257, 10999944, 11241319, 11725533, 11779172, 12042667, 12223434, 12749606, 12844137, 14981342, 15265511, 15308589, 15475735, 15660270, 15940289, 15980104, 16272956, 16402128, 16452582, 16891249, 16952495, 17130279, 17220563, 18212800, 18380793, 18698229, 19225447, 19238117, 19604090, 19845430, 19921195, 20089352, 20155256, 20596643, 21494765, 21521021, 10448083
PA165924731CYP2A6*7HaplotypeVipGeneassociated11779172, 15308589, 15592323, 15900015, 15980104, 16952495, 17220563, 18380793, 19225447, 19238117, 19604090, 19845430, 19921195, 20596643, 21494765, 21521021, 11237731
PA165924735CYP2A6*10HaplotypeVipGeneassociated15308589, 15980104, 16952495, 19225447, 19921195, 21521021, 11779172
PA165924744CYP2A6*17HaplotypeVipGeneassociated16952495, 19225447, 19238117, 20860463, 15592323
PA165924749CYP2A6*20HaplotypeVipGeneassociated18360915, 15993850
PA1659583213,5-dimethyl-2-(3-pyridyl)thiazolidin-4-oneChemicalVipGeneassociated19075994, 8627557, 10087035
PA165980914CYP2A6*9HaplotypeVipGeneassociated12844137, 15475735, 15660270, 15980104, 16402128, 16452582, 16952495, 17112802, 17130279, 17220563, 18698229, 19225447, 19238117, 19604090, 19845430, 19921195, 20155256, 20596643, 20860463, 21494765, 21521021, 11394901
PA165980915CYP2A6*12HaplotypeVipGeneassociated15475735, 17112802, 19225447, 19238117, 12325023
PA166114414cotinineChemicalVariantAnnotationassociatedPK
PA166115442s 1 (combination)ChemicalVariantAnnotationambiguousPD29189588
PA166123026progression-free survivalDiseaseVariantAnnotationassociatedPD29189588
PA166123207overall survivalDiseaseVariantAnnotationassociatedPD29189588
PA166155376rs1801272VariantVipGeneassociated19238117
PA166155422rs5031016VariantVipGeneassociated15900015, 18380793, 18698229, 19238117, 19604090, 19921195, 20596643, 11237731
PA166155447rs8192726VariantVipGeneassociated20860463
PA166155471rs28399433VariantVipGeneassociated19238117, 19604090, 19921195, 20155256, 21521021, 18698229
PA166155475rs28399454VariantVipGeneassociated16952495, 20860463, 15592323
PA166155477rs28399468VariantVipGeneassociated19604090, 18698229
PA166169432losigamoneChemicalVipGeneassociated12386121, 14704462, 19442086, 19702528, 8886611, 11038165
PA443560Breast NeoplasmsDiseaseClinicalAnnotation, VariantAnnotationassociatedPK19845430, 21494765, 21975350, 30094551
PA443622Carcinoma, Non-Small-Cell LungDiseaseVariantAnnotationassociatedPK18212800
PA443899DiarrheaDiseaseVariantAnnotationnot associatedPD
PA443937Drug ToxicityDiseaseVariantAnnotationnot associatedPD
PA444065EpilepsyDiseaseVariantAnnotationassociatedPK20089352
PA444818Lung NeoplasmsDiseaseClinicalAnnotationassociatedPD
PA445062NeoplasmsDiseaseClinicalAnnotation, VariantAnnotation, VipGeneambiguousPKPD11960911, 12919726, 15308589, 17259654, 19018727, 19339270, 1940642, 19702528, 19823875, 21791872, 11805739, 12042667, 15900015, 18212800, 18380793, 19052543, 19921195, 21326246, 21521021
PA445113NeutropeniaDiseaseVariantAnnotationnot associatedPD
PA445742Stomach NeoplasmsDiseaseVariantAnnotationassociatedPKPD12042667, 19604090, 29189588
PA445876Tobacco Use DisorderDiseaseClinicalAnnotation, VariantAnnotation, VipGeneassociatedPKPD10899369, 10999944, 11180041, 11692077, 11805739, 11960911, 12919726, 14981342, 15229465, 15308589, 15475735, 15592323, 15734728, 15735609, 15940289, 16041240, 16272956, 16359169, 16402128, 16765148, 17130279, 17259654, 19018727, 19184652, 19251795, 19339270, 1940642, 19702528, 19793020, 19823875, 20307138, 21791872, 8627511, 8937855, 10350185, 11278503, 11779172, 12844137, 15475735, 15861035, 15900015, 15940289, 15993850, 16402128, 16952495, 17267622, 18360915, 26132489, 27599351
PA446108Colorectal NeoplasmsDiseaseVariantAnnotationnot associatedPD
PA446975Neurotoxicity SyndromesDiseaseVariantAnnotationnot associatedPD
PA447230HIVDiseaseClinicalAnnotation, VariantAnnotationambiguousPKPD19238117, 19371316, 19779319, 20860463, 22354160, 23172109, 23859571, 24080498, 24316028, 24477223, 26774523, 26779253, 31628422
PA448015acetaminophenChemicalLiterature, MultilinkAnnotation, Pathwayassociated11866476, 26049587, 9548799
PA448687bupropionChemicalClinicalAnnotationassociatedPD26132489
PA448710caffeineChemicalVariantAnnotation, VipGeneassociatedPK10544257, 10999944, 11197315, 11237731, 11241319, 11394901, 11725533, 11779172, 12042667, 12223434, 12749606, 12844137, 14981342, 15265511, 15308589, 15475735, 15592323, 15660270, 15900015, 15940289, 15980104, 16272956, 16402128, 16452582, 16891249, 16952495, 17112802, 17130279, 17220563, 17267622, 18212800, 18380793, 18698229, 19225447, 19238117, 19604090, 19845430, 19921195, 20089352, 20155256, 20596643, 20860463, 21494765, 21521021, 10448083, 15980104
PA448785carbamazepineChemicalVipGeneassociated12386121, 14704462, 19442086, 19702528, 8886611, 11038165
PA449165cyclophosphamideChemicalVipGeneassociated12386121, 14704462, 19442086, 19702528, 8886611, 11038165
PA449256dexmedetomidineChemicalVariantAnnotationnot associatedPK
PA449383docetaxelChemicalVariantAnnotationassociatedPD19604090
PA449441efavirenzChemicalClinicalAnnotation, Literature, MultilinkAnnotation, VariantAnnotation, VipGeneambiguousPKPD10544257, 10999944, 11180041, 11192870, 11237731, 11241319, 11394901, 11434509, 11684323, 11725533, 11779172, 12042667, 12223434, 12325023, 12545140, 12676886, 12749606, 12844137, 14981342, 15167626, 15225612, 15265511, 15308589, 15475735, 15592323, 15660270, 15864119, 15900015, 15940289, 15980104, 16272956, 16402128, 16452582, 16891249, 16952495, 17112802, 17130279, 17220563, 17267622, 17559344, 18212800, 18380793, 18698229, 19225447, 19238117, 19604090, 19845430, 19921195, 20089352, 20155256, 20596643, 20860463, 21494765, 21521021, 9586947, 9827545, 10448083, 19238117, 19371316, 19779319, 20860463, 22354160, 23172109, 23859571, 24080498, 24316028, 24477223, 24729586, 26774523, 26779253, 31628422
PA449845halothaneChemicalVipGeneassociated12386121, 14704462, 19442086, 19702528, 8886611, 11038165
PA449964ifosfamideChemicalVipGeneassociated12386121, 14704462, 19442086, 19702528, 8886611, 11038165
PA450085irinotecanChemicalVariantAnnotationnot associatedPD
PA450196letrozoleChemicalClinicalAnnotation, VariantAnnotation, VipGeneassociatedPK10544257, 10999944, 11180041, 11237731, 11241319, 11394901, 11434509, 11684323, 11725533, 11779172, 12042667, 12223434, 12325023, 12749606, 12802030, 12844137, 14981342, 15225612, 15265511, 15308589, 15475735, 15592323, 15660270, 15900015, 15940289, 15980104, 16272956, 16378601, 16402128, 16452582, 16891249, 16952495, 17112802, 17130279, 17220563, 18212800, 18380793, 18698229, 19225447, 19238117, 19604090, 19845430, 19921195, 20089352, 20155256, 20596643, 20860463, 21494765, 21521021, 9827545, 10448083, 19845430, 21494765, 21975350, 30094551
PA450433methoxsalenChemicalClinicalAnnotation, Literature, MultilinkAnnotation, VariantAnnotationambiguous24475091
PA450484metronidazoleChemicalClinicalAnnotation, VariantAnnotationambiguousPK
PA450626nicotineChemicalClinicalAnnotation, MultilinkAnnotation, VariantAnnotation, VipGeneambiguousPKPD10544257, 10999944, 11180041, 11237731, 11241319, 11394901, 11434509, 11684323, 11725533, 11779172, 11805739, 11960911, 12042667, 12223434, 12325023, 12749606, 12844137, 12919726, 14981342, 15225612, 15265511, 15308589, 15475735, 15592323, 15660270, 15900015, 15940289, 15980104, 15993850, 16272956, 16378601, 16402128, 16452582, 16891249, 16952495, 17112802, 17130279, 17220563, 17259654, 17267622, 18212800, 18360915, 18380793, 18698229, 19018727, 19225447, 19238117, 19339270, 1940642, 19604090, 19702528, 19823875, 19845430, 19921195, 20089352, 20155256, 20596643, 20860463, 21494765, 21521021, 21791872, 9827545, 10448083, 11278503, 11394901, 11779172, 12445030, 12844137, 15475735, 15861035, 15900015, 15940289, 15993850, 16402128, 16952495, 17267622, 18360915, 21521021, 24305170, 27599351
PA450947phenytoinChemicalVipGeneassociated12386121, 14704462, 19442086, 19702528, 8886611, 11038165
PA450962pilocarpineChemicalVariantAnnotation, VipGeneassociatedPK10544257, 10999944, 11237731, 11241319, 11394901, 11725533, 11779172, 12042667, 12223434, 12749606, 12844137, 14981342, 15265511, 15308589, 15475735, 15660270, 15900015, 15940289, 15980104, 16272956, 16402128, 16452582, 16891249, 16952495, 17112802, 17130279, 17178767, 17220563, 18212800, 18380793, 18698229, 19225447, 19238117, 19604090, 19845430, 19921195, 20089352, 20155256, 20596643, 20860463, 21494765, 21521021, 10448083, 18698229
PA451846valproic acidChemicalVariantAnnotation, VipGeneassociatedPK10544257, 10999944, 11241319, 11725533, 11779172, 12042667, 12223434, 12749606, 12844137, 14981342, 15265511, 15308589, 15475735, 15660270, 15940289, 15980104, 16272956, 16402128, 16452582, 16891249, 16945988, 16952495, 17130279, 17220563, 18212800, 18380793, 18698229, 19225447, 19238117, 19604090, 19845430, 19921195, 20089352, 20155256, 20596643, 21494765, 21521021, 3101178, 6437960, 9353388, 10448083, 20089352
PA451954zidovudineChemicalPathwayassociated22960662
PA452620tegafurChemicalClinicalAnnotation, VariantAnnotation, VipGeneambiguousPKPD10544257, 10999944, 11095583, 11106261, 11237731, 11241319, 11394901, 11725533, 11779172, 12042667, 12223434, 12749606, 12844137, 14981342, 15265511, 15308589, 15475735, 15592323, 15618749, 15660270, 15900015, 15940289, 15980104, 16272956, 16378601, 16402128, 16452582, 16891249, 16952495, 17112802, 17130279, 17220563, 18212800, 18380793, 18698229, 19225447, 19238117, 19604090, 19845430, 19921195, 20089352, 20155256, 20596643, 20860463, 21494765, 21521021, 8862723, 10448083, 12042667, 15900015, 18212800, 18380793, 19052543, 19604090, 19921195, 21326246, 21521021

References

Pubmed IDYearTitleCitations
204188882010Sequence variants at CHRNB3-CHRNA6 and CYP2A6 affect smoking behavior.368
204188882010Sequence variants at CHRNB3-CHRNA6 and CYP2A6 affect smoking behavior.368
154757352004Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians.104
154757352004Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians.104
153701552004The genetic basis for smoking behavior: a systematic review and meta-analysis.98
192795612009Association of nicotine metabolite ratio and CYP2A6 genotype with smoking cessation treatment in African-American light smokers.88
171128022006CYP2A6 genotype and the metabolism and disposition kinetics of nicotine.85
171128022006CYP2A6 genotype and the metabolism and disposition kinetics of nicotine.85
217470482011Relationship between CYP2A6 and CHRNA5-CHRNA3-CHRNB4 variation and smoking behaviors and lung cancer risk.85
160860272005Structures of human microsomal cytochrome P450 2A6 complexed with coumarin and methoxsalen.78

Citation

Naoki Inui

CYP2A6 (cytochrome P450, family 2, subfamily A, polypeptide 6)

Atlas Genet Cytogenet Oncol Haematol. 2009-12-01

Online version: http://atlasgeneticsoncology.org/gene/40240/cyp2a6-(cytochrome-p450-family-2-subfamily-a-polypeptide-6)